847 results on '"Blakeley, Jaishri"'
Search Results
2. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
3. A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas
4. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1–Associated Cutaneous Neurofibromas
5. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
6. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
7. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods
8. Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT).
9. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
10. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative.
11. CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas
12. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1
13. Telomere alterations in neurofibromatosis type 1-associated solid tumors
14. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
15. cNF-Skindex in Adults Living with Neurofibromatosis 1: Severity Strata in France and Validation in United States Adults
16. Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas
17. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics
18. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
19. Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1.
20. High‐intensity focused ultrasound: Safety and efficacy of a novel treatment modality for neurofibromatosis type 1 cutaneous neurofibroma.
21. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
22. Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients
23. Occurrence and Severity of Suicidal Ideation in Adults With Neurofibromatosis Participating in a Mind–Body RCT
24. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
25. 447 Is Surgical Management of Brachial Plexus Schwannomas Safe and Effective: A Review of Clinical Experience
26. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis
27. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis:A potential model for rare diseases
28. Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
29. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
30. Current whole-body MRI applications in the neurofibromatoses
31. Current status and recommendations for biomarkers and biobanking in neurofibromatosis
32. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1
33. Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1
34. Non-invasive Treatment of Cutaneous Neurofibromas (cNFs): Results of a Randomized Prospective, Direct Comparison of Four Methods
35. Basic and translational advances in neurofibromatosis
36. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution
37. CTNI-80. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NF2-RELATED SCHWANNOMATOSIS PATIENTS WITH PROGRESSIVE SCHWANNOMAS, MENINGIOMAS, AND EPENDYMOMAS: PRIMARY OUTCOME OF THE BRIGATINIB TREATMENT ARM
38. Brain Cancers in Genetic Syndromes
39. An update on the central nervous system manifestations of neurofibromatosis type 1
40. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis
41. Contributors List
42. Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis
43. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies
44. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
45. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
46. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials
47. Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma
48. A clinically and genomically annotated nerve sheath tumor biospecimen repository
49. Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
50. Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.